Therapeutic advances in the treatment of brain metastases

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 1, 2007, Pages 54-64

  Chang, Julie E ^a   Robins, Ian ^b   Mehta, Minesh P ^b  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Motexafin gadolinium; Radiosurgery; Radiotherapy; RSR13; Surgery; Temozolomide

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EFAPROXIRAL; ERLOTINIB; ETOPOSIDE; GADOLINIUM TEXAPHYRIN; GEMCITABINE; HYDROXYUREA; INTERLEUKIN 2; IRINOTECAN; LAPATINIB; LOMUSTINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE; TENIPOSIDE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN DYSFUNCTION; BRAIN METASTASIS; BREAST CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEMENTIA; DRUG BIOAVAILABILITY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; QUALITY OF LIFE; SOLID TUMOR; STEREOTAXIC SURGERY; SURVIVAL RATE; TOXIC HEPATITIS;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COGNITION DISORDERS; HUMANS; RADIOSURGERY; RANDOMIZED CONTROLLED TRIALS;

EID: 33847355571     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Wen PY, Black PM, Loeffler JS: Metastatic Brain Cancer, in DeVita V, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippincott, Williams, & Wilkins, 2001, pp 2655-2670.
2. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91:639-643.
3. Burton RC, Coates MS, Hersey P, et al. An analysis of a melanoma epidemic. Int J Cancer. 1993;55:765-770.
4. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol. 1999;135:275-280.
5. Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest. 2005;128:370-381.
6. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol. 1999;44:275-281.
7. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1-9.
8. Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG 7916). Int J Radiat Oncol Biol Phys. 1991;20:53-58.
9. Sause WT, Scott C, Krisch R, et al. Phase I/II trial of accelerated fractionation in brain metastases (RTOG 8528). Int J Radiat Oncol Biol Phys. 1993;26: 653-657.
10. Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard fractionation in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG 9104). Int J Radiat Oncol Biol Phys. 1997;39:571-574.
11. Mehta MP, Tsao MN, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63:36-46.
12. Störtebecker TP. Metastatic rumors of the brain from a neurosurgical point of view: a follow-up study of 158 cases. J Neurosurg. 1954;11:84-111.
13. Vieth RG, Odom GL. Intracranial metastases and their neurosurgical treatment. J Neurosurg. 1965;23:375-383.
14. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44: 1913-1918.
15. Hendrickson FR, Lee MS, Larson M, Gelber RD. The influence of surgery and radiation therapy on patients with brain metastases. Int J Radiat Oncol Biol Phys. 1983;9:623-627.
16. Sundaresan N, Galicich JH, Beattie EJ Jr. Surgical treatment of brain metastases from lung cancer. J Neurosurg. 1983;58:666-671.
17. Patchell RA, Cirrincione C, Thaler HT, et al. Single brain metastases: surgery plus radiation or radiation alone. Neurology. 1986;36:447-453.
18. Mandell L, Hilaris B, Sullivan M, et al. The treatment of single brain metastasis from non-oat cell lung carcinoma: surgery and radiation versus radiation therapy alone. Cancer. 1986;58:641-649.
19. Montana GS, Meacham WF, Caldwell WL. Brain irradiation for metastatic disease of lung origin. Cancer. 1972;29:1477-1480.
20. Berry HC, Parker RG, Gerdes AJ. Irradiation of brain metastases. Acta Radiol Ther Phys Biol. 1974;13:535-544.
21. Markesbery WR, Brooks WH, Gupta GD, Young AB. Treatment for patients with cerebral metastases. Arch Neurol. 1978;35:754-756.
22. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500.
23. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711-717.
24. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78:1470-1476.
25. Sturm V, Kober B, Hover KH, et al. Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. Int J Radiat Oncol Biol Phys. 1987;13:279-282.
26. Loeffler JS, Kooy HM, Wen PY, et al. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol. 1990;8:576-582.
27. Fuller BG, Kaplan ID, Adler J, et al. Stereotaxic radiosurgery for brain metastases: the importance of adjuvant whole brain irradiation. Int J Radiat Oncol Biol Phys. 1992;23:413-418.
28. Mehta MP, Rozental JM, Levin AB, et al. Defining the role of radiosurgery in the management of brain metastases. Int J Radiat Oncol Biol Phys. 1992;24: 619-625.
29. Flickinger JC, Kondziolka D, Lunsford LD, et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys. 1994;28:797-802.
30. Alexander E, Moriarty TM, Davis RB, et al. Stereotactic radiosurgery for the definitive non-invasive treatment of brain metastases. J Natl Cancer Inst. 1995;87:34-40.
31. Auchter RM, Lamond JP, Alexander E, et al. A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys. 1996;35:27-35.
32. Engenhart R, Kimmig BN, Hover K, et al. Long-term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation. Cancer. 1993;71:1353-1361.
33. Kihlstrom L, Karlsson B, Lindquest C, et al. Gamma knife surgery for cerebral metastases: the importance of adjuvant whole brain irradiation. Acta Neurochir Suppl. 1991;52:89.
34. Shiau CY, Sneed PK, Shu HK, et al. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys. 1997;37:375-383.
35. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(2):427-434.
36. Shu HK, Sneed PK, Shiau CY, et al. Factors influencing survival after gamma knife radiosurgery for patients with single and multiple brain metastases. Cancer J Sci Am. 1996;2:335-342.
37. Sanghavi SN, Miranpuri SS, Chappell R, et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001;51:426-434.
38. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
39. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet. 2004;363:1665-1672.
40. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-2491.
41. Manon R, O'Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E6397). J Clin Oncol. 2005;23:8870-8876.
42. Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys. 1999;43: 549-558.
43. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002;53:519-526.
44. Regine WF, Huhn JL, Patchell RA, et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys. 2002;52:333-338.
45. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485-1489.
46. DeAngelis LM, Mandell LR, Thaler HT. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery. 1989;24:798-805.
47. Mehta MP, Rodrigues P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529-2536.
48. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157-165.
49. Ott RJ, Brada M, Flower MA, et al. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer. 1991;27:1356-1361.
50. Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol. 1994;20:121-139.
51. Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small cell lung cancer to systemic first-line chemotherapy. J Clin Oncol. 2006;24(13):2079-2083.
52. Kortmann RD, Jeremic B, Weller M, et al. Radiochemotherapy of malignant gliomas in adults: Clinical experiences. Strahlenther Onkol. 2003;179:219-232.
53. Patel M, McCully C, Godwin K, et al. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol. 1995;14:461a.
54. Agarwala S, Reyderman L, Statkevich P, et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol. 1998; 9(suppl 4):138a.
55. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81:1022-1030.
56. Newlands ES, O'Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996;32:2236-2241.
57. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide. Br J Cancer. 1992;65:287-291.
58. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer. 1993;29:940-942.
59. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
60. Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide versus procarbazine in a patient with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
61. Middleton MR, Grobb JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patient with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
62. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
63. Siena S, Landonio G, Baietta E, et al. Multicenter phase II study of temozolomide therapy for brain metastatses in patients with malignant melanoma, breast cancer, and non-small cell lung cancer. Proc Am Soc Clin Oncol. 2003. Abstract 407.
64. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med. 2001;345:621-622.
65. Dardoufas C, Miliadou A, Skarleas C, et al. Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumors. Proc Am Soc Clin Oncol. 2001. Abstract 2048.
66. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Onc. 2002;20:3644-3650.
67. Antonadou D, Coliarakis N, Paraskevaidis M, et al. Whole brain radiotherapy alone or in combination with temozolomide for brain metastases: a phase III study. Int J Radiat Oncol Biol Phys. 2002;54(suppl 1):93-94.
68. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 2001;12:249-254.
69. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001;53:259-265.
70. Friedman HS, Evans B, Reardon D, et al. Phase II trial of temozolomide for patients with progressive brain metastases. Proc Am Soc Clin Oncol. 2003. Abstract 408.
71. Giannitto-Giorgio C, Giuffrida D, Cordio S, et al. Oral temozolomide may induce prolonged survival in patients affected by non-small cell lung cancer brain recurrences that progressed after whole-brain radiotherapy. Ann Oncol. 2002;13(suppl 5). Abstract 541.
72. Giannitto-Giorgio C, Cordio S, Di Blasi C, et al. Temozolomide shows promising activity against pretreated brain recurrences of non-small cell lung cancer. Preliminary results of a phase II trial. Proc Am Soc Clin Oncol. 2002;21. Abstract 2779.
73. Mangiameli A, Giuseppe M, Guglielmo MT, et al. Temozolomide (TMZ) in patients with brain metastases from NSCLC in combination with gemcitabine-cisplatin (GEM-CDDP) or gemcitabine-vinorelbine (GEM+VNB). Proc Am Soc Clin Oncol. 2001;20:261b.
74. Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003;8:69-75.
75. Adonizio CS, Babb JS, Maiale C, et al. Temozolomide in non-small cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer. 2002;3:254-258.
76. Choong NW, Mauer AM, Hoffman PC, et al. Phase II trial of temozolomide and irinotecan as second line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006;1(3):245-251.
77. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6:1474-1480.
78. Newman SJ, Hansen HH. Proceedings: frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974;33:492-496.
79. Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol. 1999;17:2700-2709.
80. Robnett TJ, Machtay M, Stevenson JP, et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol. 2001. 19:1344-1349.
81. Robins HA, Traynor AM, Mehta MP. Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer. J Thorac Oncol. 2006;1:732-733.
82. Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol. 2006;78: 255-260.
83. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85:1599-1605.
84. Boogerd W, van der Sande JJ, van Zandwijk N. Teniposide sometimes effective in brain metastases from non-small cell lung cancer. J Neurooncol. 1999;41: 285-289.
85. Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy: a phase III study of the European Organization for the Research and Treatment of Cancer, Lung Cancer Cooperative Group. J Clin Oncol. 2000;18:3400-3408.
86. Korfel A, Oehm C, von Pawel J, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: a multi-center phase II study. Eur J Cancer. 2002;38:1724-1729.
87. Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 2002;20: 293-302.
88. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12:59-67.
89. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005;23:2955-2961.
90. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol. 2006;24(18S). Abstract 503.
91. Kleinberg L, Grossman SA, Carson K, et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II New Approaches to Brain Tumor Therapy CNS Consortium safety and efficacy study. J Clin Oncol. 2002;20:3149-3155.
92. Teicher BA, Ara G, Emi Y, et al. RSR13: effects on tumor oxygenation and response to therapy. Drug Dev Res. 1996;38:1-11.
93. Suh J, Stea B, Nabid A, et al. Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral) in patients with brain metastases: results of the randomized REACH (RT-009) study. Proc Am Soc Clin Oncol. 2004. Abstract 1534.
94. Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol. 2003;21:2364-2371.
95. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006; 24: 106-114.
96. Rodrigus P. Motexafin gadolinium: a possible new radiosensitizer. Expert Opin Investig Drugs. 2003;12:1205-1210.
97. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys. 2001;51:1025-1036.
98. Viala J, Vanel D, Meingan P, et al. Phases Ib and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology. 1999;212:755-759.
99. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium rexaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res. 1999;5:739-745.
100. Carde P, Timmerman R, Mehra MP, et al. Multicenter Phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 2001;19:2074-2083.
101. Mehta MP, Carrie C, Mahe MA, et al. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a Phase 3 trial. Int J Radiat Oncol Biol Phys. 2006;66(suppl). Abstract 41.
102. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Rad Oncol Biol Phys. 2005;61:185-191.
103. Langer CJ, Mehta MP. Current management of brain metastases with a focus on systemic options. J Clin Oncol. 2005;23:6207-6219.